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A b s t r a c t
The traditional method of classifying neurodegenerative diseases is based on the original clinico-pathological concept
supported by ‘consensus’ criteria and data from molecular pathological studies. This review discusses first, current prob-
lems in classification resulting from the coexistence of different classificatory schemes, the presence of disease hete-
 rogeneity and multiple pathologies, the use of ‘signature’ brain lesions in diagnosis, and the existence of pathologi-
cal processes common to different diseases. Second, three models of neurodegenerative disease are proposed: (1) that
distinct diseases exist (‘discrete’ model), (2) that relatively distinct diseases exist but exhibit overlapping features (‘over-
lap’ model), and (3) that distinct diseases do not exist and neurodegenerative disease is a ‘continuum’ in which there
is continuous variation in clinical/pathological features from one case to another (‘continuum’ model). Third, to dis-
tinguish between models, the distribution of the most important molecular ‘signature’ lesions across the different 
diseases is reviewed. Such lesions often have poor ‘fidelity’, i.e., they are not unique to individual disorders but are dis-
tributed across many diseases consistent with the overlap or continuum models. Fourth, the question of whether the
current classificatory system should be rejected is considered and three alternatives are proposed, viz., objective clas-
sification, classification for convenience (a ‘dissection’), or analysis as a continuum.
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Introduction
The traditional method of classifying neurode-
generative diseases is based on the original clinico-
pathological concept, viz., a disease entity is a specific
combination of clinical features and a distinctive
neuropathology [40,45,59]. It was this principle, origi -
nally applied to small numbers of cases, that result-
ed in the first descriptions of Alzheimer’s disease (AD)
[1,60], Pick’s disease (PiD) [116], dementia with Lewy
bodies (DLB) [45,87], Creutzfeldt-Jakob disease (CJD)
[32,75], and progressive supranuclear palsy (PSP)
[128]. Subsequently, the definition of these diseases
has been refined and modified by two further develop-
ments. First, the establishment of ‘consensus criteria’
the aim of which was to achieve agreement among
leading experts regarding the clinical and patholo -
gical features most useful in diagnosis [90,95,133]. 
Second, the discovery of disease-specific antibodies
enabled aggregates of insoluble and/or misfolded pro-
teins to be detected and therefore the molecular 
‘signature’ of brain lesions to be established [46]. As
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a result, neurodegenerative diseases are often regard-
ed as relatively distinct ‘entities’. In this traditional mo -
del, cases that exhibit the features of more than one
disorder (‘multiple pathologies’), e.g. DLB in combination
with AD [52], are often considered to represent the co-
occurrence of common neuropathologies [16]. 
Two aspects of recent studies have questioned the
validity of the traditional model, viz., the degree of hete-
rogeneity commonly observed within disorders and 
the extent of the overlap or ‘interface’ between them
[6,16,42,45,61]. Overlap between neurodegenerative 
disorders is defined as the coexistence of clinical and/or
neuropathological features of more than one disorder
in the same individual case [16]. Hence, multiple pa -
tho logical processes are common in dementia cases
and significantly affect the clinical presentation of the
disease [144]. If there is extensive overlap, it raises
a question of the ‘distinctiveness’ of the individual dis-
eases and therefore, how they may be classified. Some
closely related neurodegenerative diseases may even
be ‘unclassifiable’ and essentially form a ‘continuum’
in which there is a gradual clinical and pathological
change from one case to another [6]. The frequent use
by authors of such terms as ‘complex syndrome’ [30,
49,132], ‘spectrum of disorders’ [50], or even ‘continu-
um’ [30,49,132] testifies to the extent to which the
boundaries between different disorders may in reali-
ty be more indistinct than previously thought. 
This review considers various aspects of the ques-
tion of how neurodegenerative disease should be ‘clas-
sified’. First, the traditional clinico-pathological concept
is described and problems resulting from the coexis-
tence of different classificatory schemes, the presence
of disease heterogeneity, the use of ‘signature’ brain
lesions in diagnosis, and pathological processes com-
mon to different diseases are discussed. Second, three
models of neurodegenerative disease are proposed, viz.,
(1) that distinct diseases exist (‘discrete’ model), (2) that
distinct diseases exist but exhibit overlapping features
(‘overlap’ model), and (3) that distinct diseases do not
exist and neurodegenerative disease forms a ‘conti -
nuum’ in which there is continuous variation in clini-
cal/pathological features from one case to another
(‘continuum’ model). Third, the distribution of the major
molecular ‘signature’ lesions among the different di -
sease entities is reviewed. Fourth, the question of whet -
her the current classification of neurodegenerative 
disease should be rejected is discussed and three alter-
native conceptual systems are proposed, viz., objec-
tive classification, classification for convenience (a dis-
section), or analysis as a continuum.
Traditional method of classification
Clinico-pathological concept
The original description of some disorders was
based on studies of small numbers of cases and on the
correlation of clinical symptoms with neuropathology.
Hence, the original clinico-pathological description 
of AD originated in Alzheimer’s detailed report of 1907
[1] of a case of presenile dementia associated with the
presence of numerous senile plaques (SP) and neuro -
fibrillary tangles (NFT) [59,60]. Similarly, the descrip-
tion of PiD was based on a series of patients charac-
terised by cognitive disturbance, personality change
and focal symptoms [116] and DLB on the description
of patients by Lewy with ‘paralysis agitans’ accom-
panied by the formation of SP and NFT [45,87]. Sim-
ilarly, PSP was defined as an entity in 1964 based on
nine cases of progressive brain disease [84,128]. No -
tably, many of these disorders were not described ori -
ginally as ‘discrete’ diseases by the original investigators
who often interpreted such cases as examples of more
complex ‘syndromes’.
Consensus criteria 
Consensus criteria, the purpose of which was to pro-
vide a set of agreed objective criteria for diagnosis, have
now been established or proposed for the majority 
of neurodegenerative diseases. Hence, AD is diagnos -
ed according to the ‘National Institute of Neurological
and Communicative Disorders and Stroke and Alz -
heimer’s Disease and Related Disorders Association’
(NINCDS/ADRDA [133], the histological diagnosis
being established by the presence of widespread neo-
cortical senile plaques (SP) consistent with the ‘Con-
sortium to Establish a Registry of Alzheimer’s Disease’
(CERAD) criteria [98] and now extended by the NIA-Rea-
gan Institute criteria [76]. DLB is diagnosed according
to the ‘Consortium on Dementia with Lewy bodies’
(CDLB) guidelines for DLB [96], and PSP by the Natio -
nal Institute of Neurological Disorders and Stroke
(NINDS) and the Society of PSP (SPSP) [68,90,91]. Re -
cently, consensus criteria have also been proposed for
many of the disorders included within frontotempo-
ral dementia (FTD) and its pathological substrate fron-
totemporal lobar degeneration (FTLD) [29].
Molecular pathology
The major molecular constituents of brain lesions,
e.g., β-amyloid (Aβ, tau, and α-synuclein have play -
ed a defining role in diagnosis and classification. In
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some disorders, a direct link has been postulated bet -
ween the presence of a specific gene mutation and the
formation of a ‘signature’ brain lesion. Hence, muta-
tions of the amyloid precursor protein (APP) [31,54] and
presenilin (PSEN) genes PSEN1 [126] and PSEN2 [86],
have been linked to familial forms of AD (FAD), the tau
gene (MAPT) to FTD with parkinsonism linked to 
chromosome 17 (FTDP-17) [119], and α-synuclein [143],
leucine-rich repeat kinase 2 (LRRK2) [143], and PARK7
(DJ-1) [112] genes to familial forms of Parkinson’s dis-
ease (PD). In addition, the majority of familial cases of
FTLD with ubiquitin-immunoreactive and tau-negative
inclusions (FTLD-U), are associated with mutations of
the progranulin (GRN) gene [21,24,33,102,118], with
smaller numbers of cases associated with valosin-con -
taining protein (VCP) gene mutation [47] or variants
in the ubiquitin associated binding protein 1 (UBAP1)
gene [93,121].
Originally, the majority of neurodegenerative dis-
orders were classified into two major molecular
groups, viz., the tauopathies: AD, PiD, argyrophilic grain
disease (AGD) [123], PSP, corticobasal degeneration
(CBD), and FTDP-17; and the synucleinopathies, viz., 
PD, DLB, and multiple system atrophy (MSA) [55]. 
Subsequently, cases that did not possess either tau or 
α-synuclein-immunoreactive inclusions were reported.
First, a proportion of FTLD-U cases were shown to have
inclusions immunoreactive to the product of the tran-
scriptor repressor gene (TARDP), viz. transactive re -
sponse (TAR) DNA-binding protein of 43kDa (TDP-43)
[107] and these cases are now referred to as TDP-43
proteinopathy (FTLD-TDP). Second, neuronal interme -
dia te filament inclusion disease (NIFID) was original-
ly associated with inclusions containing epitopes of
ubiquitin and neuronal intermediate filament (IF)
pro teins such as α-internexin (INT) [17,18,25,27,77]. 
Subsequently, these cases have also been shown to
be associated with the product of the ‘fused in sarcoma’
(FUS) gene [108] which is also implicated in familial
amyotrophic lateral sclerosis (FALS) with FUS mutation
[83,139,140], basophilic inclusion body disease (BIBD)
[103], and atypical FTLD with ubiquitin-immunoreac-
tive inclusions (aFTLD-U) [109].
Problems arising from the traditional
model
Problems of classification
Problems arising from the clinico-pathological
concept are well illustrated by FTD, the second most
common cause of dementia in industrialised countries
[29]. Recent genetic and molecular data have led to con-
siderable changes in the classification and nomenclature
within this group [29]. Hence, discrimination between
the different entities is often only possible using neu-
ropathological criteria, the majority of which are bas -
ed on the morphology and molecular composition of
‘signature’ inclusions such as neuronal cytoplasmic
inclusions (NCI), neuronal intranuclear inclusions (NII),
and glial inclusions (GI) including glial cytoplasmic inclu-
sions (GCI) and astrocytic ‘plaques’ [106]. 
FTD is a clinical diagnosis and FTLD is an ‘umbrella
term’ used for the currently identified neuropathological
variants [29,137]. The clinical variants of FTD include
the behavioural variant, the language variants, e.g.,
semantic dementia (SD) and primary progressive apha-
 sia (PPA), and motor variants such as CBD and motor
neuron disease (MND). The pathological variants of
FTLD include those with tau, ubiquitin, TDP-43, and 
FUS-immunoreactive inclusions [29]. The clinical fea-
tures of FTD, however, may not predict their patholo -
gy and neuropathological features alone cannot esta -
blish a diagnosis of FTD. Hence, some authors consider
FTD to define a group of cases loosely united by clini -
cal presentation but with heterogeneous pathologies
[62] and therefore, cannot be described by strict clin-
ico-pathological criteria alone. Recent studies have also
questioned whether some of the present members of
the group should be classified within FTD. For exam-
ple, CBD is a predominantly extrapyramidal motor 
disorder in which there is a poor correlation between
neuropathology and clinical syndrome [95]. A further
problem is posed by cases exhibiting frontal lobe de -
mentia but accompanied by a typical motor neuron dis-
ease (MND)-type pathology not typical of any single
entity currently classified within FTD [25]. Hence, FTD
represents a range of clinical syndromes that do not
map reliably onto the spectrum of recognised patholo-
gies [70,80] and therefore challenge the convention-
al clinico-pathological concept. 
The coexistence of different
classificatory schemes
Genetic and molecular biological data have played
a crucial role in diagnosis [81]. In AD, for example, iden-
tification of Aβ was made by purification from con-
gophilic angiopathy or SP [57]. Subsequently, the study
of a small number of early-onset familial cases re veal -
ed them to be linked to mutations of the APP gene
[31,54] resulting in β-amyloid (Aβ) being identified as
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the ‘signature’ lesion of the disease [53]. In addition,
the presence of tau-immunoreactive NFT in AD sepa-
rates the disorder from DLB, which possesses α-sy nu -
clein-immunoreactive inclusions, the two disorders
therefore, being distinct at the molecular level [129].
Nevertheless, advances in genetics and molecular bio -
logy also suggest that the traditional concept accom-
modates clinically and pathologically heterogeneous
conditions within the same group [44].
The initial division of disorders into tauopathies and
synucleinopathies established a molecular classifica-
tion of disease that may be at variance with that of the
traditional concept. As a consequence, the classifica-
tion of the tauopathies has altered considerably. For
example, Sergeant et al. [124] recognised three groups
of tau diseases, viz., AD, PiD and PSP/CBD and sug-
gested that the clinical phenotype was correlated with
specific tau isoforms expressed in vulnerable neuronal
populations. Tolnay and Probst [134], however, identified
the major tauopathies to be AD, AGD, PiD, PSP, and
CBD and included them as one of their four ‘main’ cat-
e gories of neurodegenerative disease, viz., tauopathies,
synucleinopathies, polyglutamine diseases, and diseases
with ubiquitin-immunoreactive inclusions, the latter be-
ing the most frequent, and now identified as FTLD-TDP
[29]. Subsequently, a more detailed classification of the
tauopathies was proposed by Trojanowski and Dick-
son [137]. Hence, cases with tau-immunoreactive in -
clusions composed of three-repeat (3R) tau were like-
ly to be PiD or FTDP-17; tau-immunoreactive inclusions
composed of four-repeat (4R) tau CBD, PSP, or FTDP-17;
while lesions composed of both 3R and 4R-immuno -
reactive tau NFT-dementia or FTDP-17. In addition, FTLD-
U cases immunoreactive for TDP-43 were FTLD-TDP with
or without MND. Nevertheless, there is substantial over-
lap between these disorders [16] suggesting they may
not be in reality distinct entities.
Cases continue to be described that are difficult 
to reconcile with any proposed classification of the tauo -
pathies. For example, cases of a familial presenile de -
mentia with bitemporal atrophy linked to exon 13 muta-
tions of the tau gene have been described [111]. Patients
exhibit early memory impairment and pronounced lobar
atrophy but the disease ultimately deve -lops into a typ-
ical AD-type dementia. This is an exam ple of the type
of case in which genetic/molecular data and the tra-
ditional clinical classification may be at variance. The
tra ditional diagnosis would suggest AD but the genet-
ic diagnosis would be FTD with tau mutation. Although
both β-amyloid and tau are amyloid proteins, such cas-
es also raise the question as to whether AD should be
considered to be a β-amyloid disease, a tauopathy, or
both? Moreover, DLB is classified as a synucleinopa-
thy and is therefore distinct from AD at the molecu-
lar level, but in clinical features and in the presence
of associated Aβ pathology, there is a considerable
degree of overlap with AD [12,14]. In fact, many DLB
cases have associated AD pathology and are often con-
sidered to be ‘mixed’ cases combining the features of
both disorders and termed DLB/AD [52]. Similarly,
should CBD and PSP be classified as 4R tauopathies
or as tau ‘variants’ within a clinical group characterised
by ‘parkinsonism’, and therefore, clinically, linked
with the synucleinopathies PD, DLB, and MSA which
also exhibit ‘parkinsonian’ type symptoms? 
Disease heterogeneity 
The presence of disease heterogeneity, viz., vari-
ation in clinico-pathological features between individual
cases classified within the same group, is a major cause
of overlap [16]. This problem is particularly acute in AD.
Early DSM-III criteria for AD greatly broadened the def-
inition of the disease and the effect of this can be seen
by examining, for example, the relationship between
AD and DLB. Hence, if there is continuous variation from
one disorder to another and if ‘restrictive criteria’ are
used to define the typical phenotypes of AD and DLB,
then it is inevitable that there will be a significant num-
ber of intermediate cases which do not fall naturally
into either of the defined categories. It may then be
necessary to define and name the intermediates, e.g.,
‘mixed’ DLB/AD [52]. If ‘broad criteria’ are used, in con-
trast, then the degree of heterogeneity now contained
within each of the groups will result in overlapping cli -
ni cal and pathological features and the presence of
a significant interface in which there are varying con-
tributions of the two pathologies. In either of these
models, the problem is how to describe and classify
the intermediate cases.
The use of ‘signature’ inclusions 
in diagnosis
Studies of familial cases of disease, and subse-
quently of the molecular composition of the resulting
inclusions, resulted in the identification of ‘signature’
pathological lesions, the presence and/or absence of
which have become an important criterion in neuro -
pathological classification. Hence, Aβ, the protease
resistant form of prion protein (PrPsc), three-repeat (3R)
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and four-repeat (4R) tau, α-synuclein, TDP-43, and FUS
are currently recognised as the most important mole -
cular markers of disease. There are several problems
resulting from this approach [7,19]. First, inclusions often
comprise several molecular constituents and therefore
the scientific basis for using any individual marker in
classification has to be established. Second, when many
chemical constituents are present, there is the prob-
lem of distinguishing the primary ‘pathological’ pro-
tein from the breakdown products of the cell, and com-
pounds acquired later by binding to existing proteins
[19]. Familial cases have usually provided the strongest
evidence of the ‘primary’ pathogenic protein, the results
then being extrapolated to sporadic disease of simi-
lar phenotype. Many primary ‘pathogenic’ proteins,
however, may themselves be deposited as a conse-
quence rather than being the cause of cellular degen-
eration, although in more common sporadic disease
it is more likely that abnormal protein deposition is
causative [15,19]. Third, the chemical composition of
an inclusion may change as the disease develops and
activity of the primary protein may decrease or be -
come substantially altered with time, which may affect
the classification of longer duration cases [19]. Fourth,
data are limited regarding the densities of ‘signature’
inclusions across disease entities and therefore, on their
degree of ‘fidelity’ to a specific disease. Fifth, quanti-
tative information on the densities of signature inclu-
sions in control cases is often lacking and therefore,
the potential occurrence of the lesions as a conse-
quence of normal aging.
Similar pathogenic cascades in different
diseases
A genetic cause has been identified in familial forms
of many diseases including AD, PD, Huntington’s dis-
ease (HD), ALS, FTLD, prion disease, and in many ataxic
syndromes [65]. In these diseases, a pathogenic
model is often proposed in which genetic change ini-
tiates a cascade of events leading to the accumulation
of an abnormally folded and/or aggregated protein
resulting in cell death [46]. There may be relatively few
cellular pathways, however, leading to cell death in dif-
ferent diseases, and as a consequence, diseases clas-
sified within different groups may have pathological
mechanisms in common. In the tauopathies, for
example, phosphorylated tau occurs in several of the
diseases leading to the accumulation of 3R and 4R-tau-
immunoreactive inclusions. In addition, recent studies
of ALS have led to the concept of the ‘clinico-patho-
logical spectrum’ and to include groups that are like-
ly to share the same aetiology such as progressive lat-
eral sclerosis (PLS), progressive muscular atrophy
(PMA), ALS-dementia, and ALS-frontal lobe dementia
[73]. These diseases are all likely to be syndromes ex -
hibiting a similar pathogenic cascade in which the
resulting clinical phenotype depends largely on ana -
tomical selectivity [73]. Hence, common pathological
processes blur the ‘distinctiveness’ of disorders caus-
ing overlap and may even result in a continuum bet -
ween some traditional disorders. 
Three models of neurodegenerative
disease
In the light of these concerns, three possible mo -
dels of neurodegenerative disease are proposed: (1) that
distinct diseases exist (‘discrete’ model), (2) that dis-
tinct diseases exist but exhibit overlapping features
(‘overlap’ model), and (3) that distinct diseases do not
exist and neurodegenerative disease is a ‘continuum’
in which there is continuous variation in clinical/patho-
logical features from one case to another (‘continuum’
model). The three models are illustrated in Fig. 1.
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Fig. 1. Three models of neurodegenerative disease
based on the theoretical distribution of three
cases each representing a different disorder: 
(A) the three cases are classified into three cat-
egories of disease with little overlap between
them (‘discrete’ model), (B) each case falls more
or less into three categories of disease but ex -
hibit overlapping features (‘overlap’ model), and
(C) the three cases do not fall into separate cate -
gories but show a continuous change from one
case to another (‘continuum’ model).
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Discrete model
If disorders are distinct from each other, then there
should be clinical and pathological features unique to
each disorder with little overlap between them (Fig. 1A).
If this model is correct, many of the clinical and patho-
logical features associated with each disorder would
be ‘constant’ or exhibit a ‘high fidelity’, i.e., they should
occur in a high percentage of cases with the disorder
and not in any other disorder. Each disorder should then
be characterised by a unique combination of clinical
and pathological features consistent with the clinico-
pathological concept. In addition, there should be po -
sitive correlations between groups of clinical and patho-
logical features leading to distinguishable disease
entities. Two different neuropathological features may
occur together if they are ‘dependent features’ i.e., 
the formation of one pathological feature directly leads
to another. For example, the ‘amyloid cascade hypo -
thesis’ of AD [64] proposes that the formation of NFT
is a direct consequence of the deposition of Aβ in the
form of SP and therefore both lesions should be char-
acteristic of AD [5]. Alternatively, two or more features
that occur together may be ‘commensal’, i.e., they are
dependent features not because one causes the
development of the other but because they require
a common pathological event for their formation. For
example, NFT in AD may not be caused by the depo-
sition of Aβ [9] but both may be the consequence of
neuronal degeneration, NFT being formed within
neuronal perikarya and its processes and SP at the
degenerating axon terminals [4,34,114].
Overlap model
Neurodegenerative disorders may be relatively
distinct but exhibit a degree of overlap in their clini-
cal and neuropathological features resulting in cases
which exhibit characteristics of both disorders (Fig. 1B).
There are many studies which support this type of mo -
del and they have been discussed in previous reviews
[6,16]. Hence, AD shares features with normal aging,
vascular dementia (VD), members of the tauopathies
and synucleinopathies, and with prion disease [6].
Hence, there is an age-related reduction in brain vol-
ume and weight, enlargement of the ventricles, and
loss of synapses and dendrites in selected areas in 
normal brain [72]. Accompanying these changes are
many of the pathological features characteristic of AD,
viz., senile plaques (SP) and neurofibrillary tangles (NFT)
[5]. The major molecular constituent of the SP is Aβ
[53] and hence, Aβ deposition in the form of diffuse
(‘pre-amyloid’), primitive, and classic (‘dense-cored’)
deposits is often regarded as a ‘signature’ patholog-
ical feature of AD [36,53]. Nevertheless, studies of Aβ
deposition have also demonstrated overlaps between
AD and normal brain [37,94]. In addition, there are over-
laps reported between the various entities which com-
prise FTD [16], and within and between the disorders
comprising the tauopathies and synucleinopathies [16].
Multiple pathologies are common in dementia cases.
For example, in a study of 45 cases, 21 (46.7%) had mul-
tiple significant pathologies with some cases exhibit-
ing three or more different pathologies [144].
Continuum model
The degree of overlap between two disorders may
become so extensive that there is essentially contin-
uous variation in clinical and neuropathological features
from one disorder to another, each case being essen-
tially unique. If neurodegenerative disease as a whole
was distributed as a strict continuum, then no two indi-
vidual cases would be identical, cases would exhibit con-
tinuous variation and as a consequence, diseases would
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Fig. 2. A Principal components analysis (PCA),
based on the densities of β-amyloid (Aβ) de po -
sits, of dementia with Lewy bodies (DLB), Famil-
ial Alzheimer’s disease (FAD), Sporadic Alz hei -
mer’s disease (SAD) and control cases, in which
cases are plotted in relation to PC1 and PC2. 
PS1 – FAD case linked to presenilin 1 mutation, 
*indi cates ‘pure’ DLB cases with little associated
Alzheimer’s disease pathology. 
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Disease Abbreviation ‘Signature’ lesions Major molecular 
determinant
Familial amylotrophic FALS NCI FUS
lateral sclerosis
Argyrophilic grain disease AGD NCI 4R tau
Alzheimer’s disease AD SP β-amyloid (Aβ)
NFT 3R/4R tau
Basophilic inclusion body BIBD GCI FUS
disease
Corticobasal degeneration CBD NCI, GCI 4R tau
Creutzfeldt-Jakob disease CJD PrP deposits PrPsc
Dementia with Lewy bodies DLB NCI α-synuclein
Down’s syndrome DS SP Aβ
NFT
FTD with parkinsonism FTDP-17 NCI 3R/4R tau
linked to chromosome 17
Frontotemporal lobar FTLD-MND NCI 4R tau
degeneration with motor
neuron disease
Frontotemporal lobar FTLD-TDP NCI TDP-43
degeneration with TDP NII TDP-43
proteinopathy
Frontotemporal lobar aFTLD-U NCI FUS
degeneration with Ub
inclusions (atypical)
Motor neuron disease MND-D GCI tau
with dementia
Multiple system atrophy MSA GCI α-synuclein
Neuronal intermediate NIFID NCI α-internexin, FUS
filament inclusion disease
Parkinson’s disease PD NFT α-synuclein
Parkinsonian-dementia Guam PDC NCI 3R/4R tau
complex of Guam
Pick’s disease PiD PB 3R tau
Progressive supranuclear PSP NCI, GCI 4R tau
palsy
Table I. Major neurodegenerative diseases, their molecular determinants, and ‘signature’ lesions
FUS – ‘fused in sarcoma’, PB – pick bodies, SP – senile plaques, NFT – neurofibrillary tangles, NCI – neuronal cytoplasmic inclusions, NII – neuronal intranuclear
inclusions, GCI – glial cytoplasmic inclusions, PrP – prion protein
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not be readily delimited as definable units (Fig. 1C).
A number of studies have used the term ‘continuum’
to describe groups of heterogeneous diseases or the
re lationships between one disease entity and another.
For example, Garraux et al. [49] reported that certain
patients with FTD developed the clinical features of 
MND and that there existed a functional continuum
between classical MND, and FTD. Talbot et al. [132] car-
ried out a single-photon emission computed tomog-
raphy (SPECT) study of classical MND, FTD/MND and
FTD and also came to the conclusion that there was
a common pattern of cortical involvement in these 
diseases which was most pronounced in FTD/MND 
and FTD.  It was subsequently concluded that these dis-
eases could represent the clinical range of a functio nal
continuum. Moreover, Caselli et al. [30] studied asym-
metric cortical degenerative syndromes (aphasic, per-
ceptive, motor, frontal lobe, bitemporal) which consti-
tute a range of atypical cortical dementias. These dis-
orders appeared to be genetically heterogeneous and
the question was raised as to whether they represented
individual syndromes or a functional continuum.
Few studies have been designed specifically to de -
monstrate whether a continuum exists between dis-
orders. As an example, β-amyloid (Aβ deposition was
quantified in the temporal lobe of elderly control cas-
es, cases of DLB, and AD [14]. A principal components
analysis (PCA) of these data suggested that the first
three principal components (PC) accounted for 26% of
the total variance. A plot of the cases in relation to PC1
and PC2 (Fig. 2) showed considerable overlap between
patient groups with no distinct boundary between the
control, DLB, and AD cases. In addition, there was no
clear boundary between FAD and sporadic AD (SAD)
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Fig. 3. The distribution of the major pathological variables across different neurodegene -
rative diseases to exhibit their ‘fidelity’. 
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although the FAD cases as a group had lower loadings
on PC2. Hence, with reference to the variable ‘Aβ depo-
sition’, control, ‘pure’ DLB, DLB/AD, and ‘pure’ AD cas-
es appear to form a continuum with no abrupt bound-
aries between the groups of cases. Whether a continuum
would still be a viable description of these cases if 
other neuropathological features were included in the
analysis, such as LB or NFT, remains to be established. 
Fidelity of pathological changes
To investigate which of the three models is the most
plausible, a comparative study of the distribution of 
the ‘signature’ inclusions across disorders would be 
necessary. If the discrete model was valid, then ‘defin-
ing’ pathological features would exhibit high ‘fidelity’
and there would be combinations of such features
linked to the same disease. By contrast, if a continuum
model is a better description, then the pathological
changes would be distributed over several diseases and
each feature would be distributed more or less inde-
pendently. The problem of this approach is the pauci-
ty of studies which examine the distribution of the var-
ious molecular signatures across disorders, and hence
there are many gaps in the literature. The ‘signature’
neuropathological lesions associated with the major
disorders, based on current data, are listed in Table I and
the distribution of the major lesions across disease enti-
ties are summarised in Fig. 3. 
Aβ deposits
Aβ deposition is regarded as the ‘signature’ lesion
of AD [53]. Nevertheless, Aβ deposits also occur in
Down’s syndrome (DS) with dementia caused by trip-
lication of the APP gene on chromosome 21 [11] and
in a proportion of cases of DLB [14]. In fact, DLB can
be divided into neocortical, limbic, cerebral, and brain-
stem types [74] and each into a ‘common’ (DLB/AD)
and ‘pure’ form based on the degree of Aβ patholo-
gy. Similar densities of Aβ deposits may be found in
AD and in DLB/AD [11] suggesting that these disorders
may represent a ‘spectrum’ of pathologies involving 
APP processing [50,58], however, concluded that the
pathology of DLB was distinct enough for it to be re -
garded as a separate disease and not a variant of AD.
This conclusion was supported by data which demon-
strated that although protease resistant, tau-immuno -
reactive paired helical filaments (PHF) were a feature
of AD, only very low densities were found in DLB [66].
In addition, Aβ pathology, neuritic plaques (NP), NFT,
and neuropil threads (NT) were studied in control sub-
jects, DLB and AD and it was concluded that apart from
the common feature of diffuse plaques, pure DLB and
AD were distinct disorders [89]. Similarly, Kawanishi
et al. [78] concluded that DLB and AD were distinct dis-
orders but with a common mechanism with reference
to amyloid formation.
In addition to DLB, Aβ pathology has been report-
ed in PD [125], PiD [125], CBD [8,125], ALS [63], and in
PSP [125]. ALS is characterised by the degeneration of
upper and lower tract motor neurons and some pa tients
also exhibit dementia or aphasia [63]. Approximately
30% of ALS cases have AD-like symptoms and some
ALS cases without overt dementia have significant AD
pathology. In ALS cases with AD pathology, Aβ deposits
are a common feature [63]. In addition, a patient with
a progressive asymmetrical parietal syndrome and the
clinical symptoms of CBD also developed the patho-
logical features of AD including Aβ deposits and phos-
phorylated tau-immunoreactive NFT [92]. A similar result
was reported by Schneider et al. [125] who reported the
presence of Aβ deposits in CBD and especially in those
cases expressing apolipoprotein E allele E4. Hence, the
pathological feature ‘Aβ deposition’ does not exhibit
‘high fidelity’ to AD but occurs across a range of disor -
ders. Studies of the overlap of pathological and clini-
cal features of patients with brain amyloidosis came to
a similar conclusion [51]. 
Neurofibrillary tangles
The second of the two original cases of ‘AD’ des -
cribed by Alzheimer was characterised by numerous SP
but lacked NFT [59]. Hence, even in the earliest des crib -
ed cases of AD there was pathological heterogeneity
raising the question as to whether ‘plaque-only’ cas-
es should be regarded as AD [99]. A large number of
dementia cases were studied by Bancher and Jellinger
[22], many being characterised by abundant NFT in the
entorhinal cortex, subiculum, and sector CA1 of the hip-
pocampus. Few SP or Aβ de posits were present in these
cases which therefore, have been referred to as NFT-
dementia. Hence, SP and NFT are neither ‘dependent’
nor ‘commensal’ lesions but appear to be distributed
relatively independently. The lack of specificity of SP
and the relative indepen dence of SP and NFT raises
a further question regarding the status of AD. First, what
pathological criteria should be used to define AD?
Jellinger and Bancher [76] recognised that defining mor-
phological criteria for AD is difficult due to phenotyp-
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ic heterogeneity, absence of specific markers, and over-
lap with related disorders [6] and suggested that both
SP and NFT should be considered as the ‘signature’
lesions of AD. Second, is there any advantage in con-
tinuing to attempt to define AD as an entity? Trojanowski
et al. [135] concluded that although AD is a ‘polygenic
dementing disorder’, there is continued merit in defin-
ing an AD phenotype as defined by progressive cognitive
impairment and the presence of SP/NFT. Nevertheless,
studies of the distribution of lesions across disorders
suggest that AD may be a part of a larger ‘continuum’
or ‘spectrum’ of neurodegenerative disease rather than
a distinct entity.
Prion deposits
Deposition of the disease form of prion protein
(PrPsc) is characteristic of the various forms of prion 
disease including Creutzfeldt-Jakob disease (CJD),
Gerstmann-Straussler-Scheinker syndrome (GSS), and
fatal familial insomnia (FFI). There are considerable sim-
ilarities, however, between the pathology of CJD and
AD [35]. In both disorders, an abnormal amyloidogenic
membrane glycoprotein is deposited as discrete extra-
cellular deposits or plaques. In addition, definite or prob-
able AD occurs in 11% of CJD patients [61]. The occur-
rence of AD pathology in CJD may be age-related but
could also represent a functional interaction between
the two pathogenic proteins [61]. In addition, Dermant
et al. [38] described a case of AD with a PSEN1 muta-
tion and an insertion of a 7-octapeptide coding repeat
within the PrP gene. Elongate cerebellar PrPsc deposits
were present but no AD pathology was observed. In
the cases reported by El Hachini et al. [41], however,
a family with a mutation at codon 163 of the PSEN1
gene, the clinico-pathological features of CJD and AD
were both present with substantial deposition of Aβ
and PrPsc. The coexistence of Aβ and PrPsc pathology
was also reported by Muramoto et al. [104] who des -
cribed a case of a 75-year-old female with conspicu-
ous AD associated with a mild form of CJD. Aβ pla ques
were present but with diffuse PrPsc immunoreactivi-
ty in the grey matter of the cerebral cortex and cere-
bellum. Similar cases were described by Barcikowska
et al. [23] in which CJD occurred together with diffuse
Aβ plaques. 
Tau-immunoreactive lesions
There are differences of opinion regarding which
entities should be included within the tauopathies. 
Cases with abundant tau-immunoreactive NFT and Aβ
deposits are usually regarded as AD while those with
tau-immunoreactive lesions but lacking Aβ deposits
comprise the ‘classical’ tauopathies viz., CBD, PSP, PiD
and FTDP-17 [85]. Tau is antigenically similar in several
of the tauopathies [127] and a number of classifications
have been proposed most notably by Trojanowski 
and Dickson [137] and Cairns et al. [29]. Nevertheless, 
the different molecular isoforms of tau do not exhi-
bit high fidelity, 4-repeat (4R) tau occurs in AD, CBD, 
PSP, FTDP-17 as well as FTLD-MND, AGC, and the parkin-
sonism dementia complex of Guam (PDC-G) [97]
while 3-repeat (3R) tau is present in AD, PiD, and PDC-G.
Tau-immunoreactive GI have also been found in ALS
with dementia [146], FTDP-17 [119], PiD [120], CBD, PSP,
parkinsonism-dementia complex and ALS of Guam
(ALS/PDC) [112], and in a few cases of MSA [131].
α-synuclein-immunoreactive lesions
α-synuclein is the major protein of the inclusions
of DLB [82] and the glial and neuronal inclusions of MSA
[113]. By contrast, relatively little α-synuclein immuno -
reactivity was recorded in AD, PiD, PSP, CBD, MND 
or in triplet-repeat disease [141]. More recently, α-synu-
clein-immunoreactive PB have been observed in the
dentate gyrus in PiD [100] and α-synuclein-immu -
noreactive NCI in the amygdala in a proportion of PDC-
Guam [145]. The use of antibodies immunoreactive to
α-synuclein, however, has revealed the coexisten ce 
of cortical LB and AD pathology in many cases of de -
mentia [130]. This conclusion was also reached by 
Trojanowski and Lee [136] who argued that the bio-
logical significance of the LB was therefore unclear. 
In addition, Lippa et al. [89] found that α-synuclein-
immunoreactive LB were present in 22% of cases of fa-
milial AD and were most numerous in the amygdala
where they coexisted with tau-immunoreactive NFT.
Similarly, in a study by Rosenberg et al. [122] of an AD
family linked to an APP717 mutation, one individual had
the limbic form of DLB, two had neocortical DLB, and
other members of the family had no LB. The presence
of LB has now been detected in 53% of post-mortems
with the APP717 mutation [122]. 
Overlap between the synucleinopathies and
tauopathies has also been reported. Hulette et al. [71],
for example, found neuropathological features char-
acteristic of clinical PD in 78 AD cases while 20% of
these cases also had features of PD pathology, i.e.,
degeneration of the substantia nigra and the presence
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of LB, neocortical LB being present in 50% of cases. 
In addition, Arai et al. [3] emphasised that AD and PD
share many common clinical and pathological features, 
α-synuclein-immunoreactive lesions being observ-
ed in 27 cases of AD. Some DS cases may also possess 
α-synuclein-immunoreactive inclusions and a number
of cases have been reported with both LB and α-synu-
clein-immunoreactive dystrophic neurites [89]. More-
over, 50% of cases in which LB were present in the
amygdala also possessed AD-type changes elsewhere
in the cerebral cortex. Argyrophilic grains immunore-
active to phosphorylated and non-phosphorylated 
tau but negative to α-synuclein have been recorded
in MSA [142]. In addition, α-synuclein-immunoreactive GI
were present but negative to phosphorylated tau.
GCI immunoreactive for α-synuclein are regarded
as the ‘signature’ lesion of MSA and helped to estab-
lish this disease as a distinct entity [113]. Similar neu-
ronal lesions and less frequent GCI, however, are also
present in DLB [39] suggesting that DLB and MSA may
be part of a disease ‘spectrum’ or ‘continuum’ that
includes both sporadic and genetic disorders. Further -
more, Takanashi et al. [131] described a patient ex hibit-
ing the pathological features of both MSA and PSP. 
The original diagnosis of this patient was MSA be cause
of the presence of numerous GCI. Nevertheless, NFT
and tufted astrocytes (TA) were also present in the basal
ganglia and brainstem thus demonstrating the coex-
istence of α-synuclein-immunoreactive inclusions in
oligodendrocytes with phosphorylated tau-immunore-
active inclusions in neurons and glia.
TDP-43 proteinopathies
The spectrum of TDP proteinopathies includes most
cases of sporadic and familial FTLD-TDP with or with-
out associated MND and also includes FTD linked to
chromosome 9p, but not FTD with charged multive -
sicular body protein 2B mutations [29]. Accumulation
of TDP-43, however, also occurs in other neurode-
generative diseases including AD [138], AGD [48], DLB
[69], ALS [26], ALS/PDC complex of Guam [67,97], and
hippocampal sclerosis (HS) [2].
FUS
Cases of NIFID were originally studied neu-
ropathologically using antibodies that recognized
either the phosphorylated neurofilament, heavy
polypeptide (NFEH) or INA [17,18,25,28,77] one of the
four proteins that comprise the type IV neuronal inter-
mediate filament (IF) proteins. Not all inclusions in NIFID,
however, are immunolabelled by anti-NFEH or INA anti-
bodies and therefore, the primary molecular defect
remains uncertain [108]. However, FUS protein has also
been shown to be a component of the inclusions of
FALS with FUS mutation [84,139,140], and two further
FTLD entities, viz., BIBD [103], and atypical FTLD with
ubiquitin-immunoreactive inclusions (aFTLD-U) [109].
Hence, FUS immunoreactivity also appears to be dis-
tributed across different disorders.
In conclusion, the distribution of molecular signa-
ture lesions across disorders suggests that many exhi -
bit poor ‘fidelity’. It is probable that with more exten-
sive data an even greater lack of fidelity would be
apparent than suggested in Figure 3. Hence, it is unlike-
ly that the discrete model is a credible description of
neurodegenerative disease. There is considerable evi-
dence, however, to support the overlap model [16] and
this overlap may be extensive enough to consider
whether neurodegenerative disease as a whole should
be considered as a continuum. 
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Fig. 4. An example of an objective ‘classification’
of Alzheimer’s disease (AD) cases into subtypes
resulting in a dendrogram. There is an initial di -
vision of cases into two groups based on the
overall density and distribution of lesions. Both
these groups can then be subdivided further
into those with and without significant capillary
amyloid angiopathy (CAA). One of the resulting
groups is then divided further based on the dis-
ease onset.
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Should a new type of ‘classification’ 
be considered?
If neurodegenerative disorders actually comprise
a series of overlapping phenotypes or even a conti -
nuum, should a new conceptual system of describing
them be considered [101,115]? More specifically, should
attempts to assign an individual case to any type of
classification be dispensed with altogether and all cas-
es of neurodegenerative disease considered as points
or ‘loci’ in a multi-dimensional continuum? Three alter-
native methods of approach are discussed, viz., objec-
tive classification, classification for convenience (a dis-
section), or analysis as a continuum.
Objective classification 
If neurodegenerative diseases are distinct entities,
it would be logical to use quantitative and statistical
methods to attempt to classify individual cases more
objectively. Hence, a ‘natural classification’ is assumed
and the objective would be to define objectively the
groupings which ‘actually’ exist. This approach has been
little used in neurodegenerative disease research to
date but an example of a classification of AD cases,
in an attempt to identify subtypes of the disease, was
described by Armstrong and Wood [10]. Cluster analy-
sis was used to classify 78 cases of AD each of which
was defined by quantitative assessment of 47 neu-
ropathological features including those of the gross
brain and the density and distribution of SP and NFT
in a range of cortical and subcortical regions. The result
was a hierarchical classification of the 78 cases dis-
played as a ‘dendrogram’ (Fig. 4). The majority of AD
cases included in the study (83%) were classified into
five subgroups which could represent phenotypic
subtypes of the disease. The advantage of such an
approach is that it can determine whether the units
(cases) are naturally classifiable into distinct groups
based on their clinical and pathological features. 
The act of ‘classification’ does not in itself, however,
answer the question of whether the cases consist of
a number of distinct entities or whether the cases
merge imperceptibly one into another. Any group of 
cases can be classified regardless of their degree 
of overlap and hence, the validity (i.e., distinctiveness)
of the resulting groups has to be independently veri -
fied. Objective classification applied to existing diseases
and based on quantitative data might support the
retention of the traditional model, indicate modifica-
tions to the system, or even suggest that classification
should be abandoned in favour of a new approach.
Classification of convenience
(‘dissection’)
Even if a considerable degree of overlap between
diseases was present, it may still be desirable to clas-
sify for ‘convenience’, i.e., it may be useful to have
a classificatory system of neurodegenerative disease
however imperfect. Such an ‘unnatural’ classification
has also been called a ‘dissection’ [79]. As an analogy,
it is often convenient to show the relief of a geogra-
phical area in the form of a map with contour layer
colouring. No person examining such a map, however,
would suppose that the boundaries between colours
represented stepwise discontinuities in elevation of the
ground [117]. Hence, in such a system it would be nec-
essary to establish the boundaries between diseases,
i.e., the contours, and then to apply them to the clas-
sification of individual cases regardless of the degree
of overlap or continuous variation.
Continuum
Classification may be considered to be an inap-
propriate or even an undesirable method of approach
in the presence of extensive overlap or a continuum.
Nevertheless, there still remains the problem of pro-
viding a suitable conceptual system of describing neu-
rodegenerative disease that is useful to clinicians and
researchers. One possible method is to use a non-hie -
rarchical system based on ‘ordination’, i.e., by arrang-
ing cases of disease with reference to a coordinate
frame so that the interrelationships between cases are
spatially represented [117]. Such methods have been
used to examine the degree of neuropathological 
heterogeneity in cases of AD [13] and FTLD-TDP [20]
and often reveal a continuum but have not to date 
been used to provide a conceptual framework for the
‘classification’ of neurodegenerative disease.
In such a system there would be no attempt to
‘name’ a disorder or to arbitrarily classify cases into
groups but only to assign an individual case to a par-
ticular region of the continuum. In a strict continuum,
all cases would be regarded as unique and the tradi-
tional disease entities would not assume any primary
importance. Location within the continuum would 
predict the biochemical pathways involved and ulti-
mately, may suggest appropriate treatment options. 
To define such a system, appropriate quantitative cri-
teria to enable an individual case to be located with
precision within the coordinate system would need to
be established. It is likely that within such a scheme,
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dementia-type disorders would segregate in a diffe -
rent area of the continuum than movement disorders.
Such an approach could also help to establish which
disorders are likely to form a continuum and which
might show greater degrees of discontinuity.
Conclusion
Three models are proposed to describe the distri-
bution of neurodegenerative disease, viz., discrete, over-
lap, and continuum models. Studies suggest varying
degrees of overlap between neurodegenerative diseases
and even the possibility of a continuum involving some
diseases [16]. Examination of the ‘signature’ lesions
commonly used to define disease entities reveals them
to have both poor ‘fidelity’ and not consistent with the
existence of discrete diseases. An important question,
therefore, is: should attempts to assign an individual
case to a pathological classification be dispensed with
altogether and all cases of neurodegenerative disease
considered as points or ‘loci’ in a multi-dimensional con-
tinuum? Three possible methods of approach are sug-
gested, viz., objective classification, classification for
convenience (a dissection), or analysis as a continu-
um. Analysis of neurodegenerative disease as a con-
tinuum may have some advantages over a traditional
classificatory scheme.
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